News headlines about Affimed (NASDAQ:AFMD) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Affimed earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.5968181992182 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Separately, Oppenheimer reiterated a “hold” rating on shares of Affimed in a research note on Friday, November 24th.
Shares of Affimed (NASDAQ AFMD) traded up $0.02 during trading on Thursday, reaching $1.40. The company had a trading volume of 121,600 shares, compared to its average volume of 190,000. Affimed has a fifty-two week low of $1.15 and a fifty-two week high of $2.95. The company has a market cap of $61.42, a PE ratio of -1.79 and a beta of 3.48. The company has a quick ratio of 6.39, a current ratio of 6.43 and a debt-to-equity ratio of 0.14.
ILLEGAL ACTIVITY WARNING: “Affimed (AFMD) Getting Somewhat Positive Media Coverage, Study Shows” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3125633/affimed-afmd-getting-somewhat-positive-media-coverage-study-shows.html.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.